

1 **Title:** Usage and awareness of antiviral medications for COVID-19

2

3 **Authors:** Kojima N<sup>1</sup> and Klausner JD<sup>2</sup>

4

5 <sup>1</sup> Department of Medicine, University of California Los Angeles, Los Angeles, 90095

6 <sup>2</sup> Department of Population and Public Health Sciences, University of Southern

7 California, Keck School of Medicine, Los Angeles, 90033

8

9 **Keywords:** COVID-19; SARS-CoV-2; Antiviral

10

11

12

13

14

15

16

17

18

19

20

21 **Corresponding Author Contact Information:**

22 Department of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA

23 90095. Email: [nkojima@ucla.edu](mailto:nkojima@ucla.edu)

24

25 Abstract

26 We surveyed people that recently tested positive for SARS-CoV-2 to assess the  
27 frequency and correlates of early treatment seeking behavior. Among high risk  
28 respondents, 66.0% were aware of treatment for COVID-19 and 36.3% had sought  
29 treatment, however only 1.7% reported use of an antiviral for SARS-CoV-2 infection.  
30 More public outreach is needed to raise awareness of the benefits of treatment for  
31 COVID-19.

32

33 Main Text

34 Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome  
35 coronavirus 2 (SARS-CoV-2), continues to cause severe disease, hospitalization, and  
36 death. There are effective means to treat SARS-CoV-2 infection [1-4], however is it not  
37 clear how often those who would benefit most use monoclonal antibodies, molnupiavir,  
38 and nirmatrelvir. We surveyed users of a national SARS-CoV-2 testing company to  
39 assess treatment awareness, treatment seeking behavior, and use of antiviral  
40 medications for those with a positive test result.

41  
42 We recruited adults (18 years or older) who had tested positive for SARS-CoV-2 by a  
43 reverse transcriptase polymerase chain reaction (RT-PCR) assay at a large clinical  
44 laboratory (Curative, San Dimas, CA). To be eligible, individuals had to have a positive  
45 RT-PCR test result within 7 days of enrollment. All surveys were anonymous and  
46 voluntary. We collected data on age, assess treatment awareness, treatment seeking  
47 behavior, and use of antiviral medications for COVID-19. Descriptive statistics were  
48 calculated on StataSE (StataCorp, College Station, TX). Advarra deemed the study IRB  
49 exempt (Pro00059961).

50  
51 There were 1,159 respondents during March 2022. Among individuals aged 65 years  
52 and older, 66.0% were aware of treatment for COVID-19 and 36.3% had sought  
53 treatment, however only 1.7% reported use of an antiviral for SARS-CoV-2 infection  
54 (Figure). Rates were similar among younger individuals.

55

56 Due to the timing of the survey, infections were most likely caused by either the  
57 Omicron variant of SARS-CoV-2 or a sublineage of the Omicron variant, which might be  
58 less severe in those with prior immunity [5]. Our findings demonstrate that increased  
59 awareness and use of antivirals among those at risk for severe disease due to COVID-  
60 19 are urgently needed among individuals that test positive for SARS-CoV-2.

61

62 Declarations

63 Declaration of competing interests

64 NK is a consultant for Curative. JDK is an independent consultant and serves as the  
65 Medical Director of Curative.

66

67 Funding

68 Curative Inc. and by a gift to the Keck School of Medicine of the University of Southern  
69 California by the W.M. Keck Foundation.

70

71 Acknowledgements

72 To the participants that donated their time.


73

74   References

- 75   1.    O'Brien MP, Forleo-Neto E, Musser BJ, et al. Subcutaneous REGEN-COV  
76        Antibody Combination to Prevent Covid-19. N Engl J Med **2021**; 385(13): 1184-  
77        95.
- 78   2.    Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early Treatment for Covid-19 with  
79        SARS-CoV-2 Neutralizing Antibody Sotrovimab. N Engl J Med **2021**; 385(21):  
80        1941-50.
- 81   3.    Whitley R. Molnupiravir - A Step toward Orally Bioavailable Therapies for Covid-  
82        19. N Engl J Med **2021**.
- 83   4.    Reis G, Dos Santos Moreira-Silva EA, Silva DCM, et al. Effect of early treatment  
84        with fluvoxamine on risk of emergency care and hospitalisation among patients  
85        with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob  
86        Health **2022**; 10(1): e42-e51.
- 87   5.    Christie B. Covid-19: Early studies give hope omicron is milder than other  
88        variants. BMJ **2021**; 375: n3144.
- 89   6.    Mahase E. Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of  
90        serious illness, company reports. BMJ **2021**; 375: n2713.

91

92 Figure. Treatment awareness, treatment seeking behavior, and use of antiviral medications among individuals 65 years  
93 and older versus individuals younger than 65 years that tested positive for SARS-CoV-2 infection in 37 States in the  
94 United States from 1 March 2022 to 30 March 2022



95

96